Literature DB >> 9417857

Lethality of pyrethrins to larvae and postlarvae of the American lobster (Homarus americanus).

L E Burridge1, K Haya.   

Abstract

Pesticide formulations containing pyrethrins are being used to treat salmonids for infestations of the copepod parasites Lepeophtherius salmonis and Caligus elongatus (sea lice). The acute lethality of one such formulation to four larval stages of the American lobster (Homarus americanus), a species of significant economic importance in eastern Canada, was determined. The formulation tested contained 0.06% pyrethrins and 0.6% piperonyl butoxide (a synergist). Stage I larvae (48-h LC50 = 4.42 microg/liter) were significantly less sensitive than stage II, III, or IV larvae. Stage II larvae (48-h LC50 = 2.72 microg/liter) were significantly less sensitive than Stage III or IV larvae. Stage III and IV larvae were not significantly different in their response to the pyrethrins formulation (48-h LC50 = 1.39 and 0.73 microg/liter, respectively). Most published studies using lobster larvae have reported that the earliest larval stage was the most sensitive to chemicals. The results described here indicate that the earliest larval stage is the least sensitive to the pyrethrins formulation. Copyright 1997 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9417857     DOI: 10.1006/eesa.1997.1571

Source DB:  PubMed          Journal:  Ecotoxicol Environ Saf        ISSN: 0147-6513            Impact factor:   6.291


  2 in total

1.  Newly Hatched Stage I American Lobster (Homarus americanus) Survival Following Exposure to Physically and Chemically Dispersed Crude Oil.

Authors:  Benjamin P de Jourdan; Tahereh Boloori; Les E Burridge
Journal:  Arch Environ Contam Toxicol       Date:  2022-01-27       Impact factor: 2.804

Review 2.  Current Research on the Safety of Pyrethroids Used as Insecticides.

Authors:  Agnieszka Chrustek; Iga Hołyńska-Iwan; Inga Dziembowska; Joanna Bogusiewicz; Marcin Wróblewski; Anna Cwynar; Dorota Olszewska-Słonina
Journal:  Medicina (Kaunas)       Date:  2018-08-28       Impact factor: 2.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.